Sign in
Taking people in United StatesPhase 2

Tests cancer treatment given at home versus in clinic for prostate cancer

Compares home and clinic cancer treatment in Black men with advanced prostate cancer.

Key facts

Who runs it
Mayo Clinic
Where
Jacksonville, United StatesSee the site
Trial code
Registry title
Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer
Status
Recruiting
Phase
Phase 2
People taking part
38 people, planned
Started
22 Jan 2026
Expected to end
29 Sept 2028
Type of study
Interventional
Treatments tested
  • Cancer Therapeutic Procedure
  • Health Care Delivery
  • Questionnaire Administration
Record updated
6 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for Black or African American men aged 18 or older with locally advanced, high-risk, biochemically recurrent or metastatic prostate cancer. They compare getting cancer treatment at home with getting it in the clinic.

Age
18 years or older
Sex
Men only
Disease stage
Locally advanced, high-risk, biochemically recurrent (PSA rising after treatment) or metastatic prostate cancer; Black or African American men
Earlier treatment
Must be receiving or about to start a standard-of-care regimen listed in the protocol, such as leuprolide, degarelix, cabazitaxel, pembrolizumab, zoledronic acid or denosumab. At least one must be given by a home health nurse. Must expect to stay on the regimen for at least 18 weeks (chemotherapy or immunotherapy) or 24 weeks (other regimens).

Main reasons for not taking part

  • Taking another investigational drug for the prostate cancer
  • Currently in hospital as an inpatient (except the Advanced Care at Home program)
  • Uncontrolled illness, such as active infection, symptomatic heart failure, unstable angina, heart rhythm problems or a heart attack within 6 months
  • Not cleared for home treatment by the social stability screening
  • Already had at-home treatment in another CCBW trial

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • Participant must be receiving a standard-of-care treatment regimen listed in this protocol that is being used in accordance with standard medical practice. Specifically, it must be either a) FDA-approved for the participant's disease indication, or b) recommended in nationally recognized professional guidelines (e.g., NCCN, ASCO, ASH, etc.) as standard of care for the disease indication. Off-label use is permitted only if supported by such guidelines
  • Black or African American male patients with locally advanced, high risk, biochemical recurrent, or metastatic prostate cancer who are currently receiving or planning to start treatment with one or more of the eligible regimens. Patients may be on any combination of these regimens, provided that at least one is administered by a home health nurse [co-administration with second generation antiandrogens, poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, oral gonadotrophin releasing hormone (GnRh) antagonists, estrogens, or older antiandrogens are allowed but combinations of oral regimens only are not permitted]; Androgen deprivation therapy (ADT):; Leuprolide intramuscular (IM) or subcutaneous (SQ), 4 or 12 weeks cycle length; Degarelix SQ, 4 weeks cycle length; Chemotherapy: Cabazitaxel IV, 3 weeks cycle length; Immunotherapy: Pembrolizumab IV, 3 weeks cycle length; Bone modifying agent + any of the prostate cancer treatments:; Zoledronic acid IV, 4 or 12 weeks cycle length; Denosumab SQ, 4 or 12 weeks cycle length
  • Patients who are anticipated to continue the treatment regimen they are currently prescribed for at least 18 weeks following registration (if on chemotherapy or immunotherapy) or 24 weeks following registration (for all other treatment regimens)
  • Residing within the area serviced by supplier
  • Provide written informed consent
  • Willing and able to comply with the study protocol in the investigator's judgement
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2 for patients on any qualifying treatment (tx) regimen; ECOG PS 0, 1, 2, or 3 for patients on ADT with or without second generation antiandrogen
  • Ability to complete questionnaire(s) by themselves or with assistance
  • Willingness to follow birth control requirements for males of reproductive potential

Who cannot take part

  • Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
  • Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
  • Patients with any severe infection within 4 weeks prior to registration including, but not limited to, hospitalization for complications of infections should not be enrolled in the trial (in the current situation, this also applies to patients with suspected or confirmed COVID-19 infection)
  • Anticipation of the need for major surgery during the course of study treatment; Note: Concomitant radiation therapy during the study period is allowed
  • Patients who received at home treatment through involvement in another CCBW trial; Note: Patients who enrolled in another CCBW trial but had to be withdrawn prior to initiating treatment in the home would still be eligible
  • Uncontrolled intercurrent illness including, but not limited to:; Ongoing or active infection; Symptomatic congestive heart failure; Unstable angina pectoris; Cardiac arrhythmia; Myocardial infarction ≤ 6 months; Wound healing disorder; Or psychiatric illness/social situations that would limit compliance with study requirements
  • Current inpatient hospitalization (excluding admission to the Advanced Care at Home program)
  • Not cleared for treatment in home via social stability screening

Where in United States

  • Mayo Clinic in FloridaJacksonville, United StatesContact: Clinical Trials Referral OfficeTaking people

About the trial

What the trial wants to find out

This phase II trial evaluates the impact of cancer therapy in the patients' home compared to in the clinic on safety, side effects, patient preference, and satisfaction in Black men with prostate cancer that has spread to nearby tissue or lymph nodes (locally advanced), that has increasing prostate-specific antigen after treatment (biochemically recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Typically drug-related cancer care is conducted at a medical center which causes patients to have to spend considerable time away from family, friends, and familiar surroundings. This separation may add to the physical, emotional, social, and financial burden for patients and their families during this difficult time in their lives. Therapy administered to a patient in the patients' residence in the comfort of familiar surrounding using Cancer Connected Access and Remote Expertise (CARE) Beyond Walls (CCBW) may help reduce psychological and financial distress, increase access to care and improve treatment compliance. Giving cancer therapy in the home compared in the clinic may be safe, tolerable and improve patient satisfaction with overall cancer care in Black men with locally advanced, biochemically recurrent or metastatic prostate cancer.

The group in the trial

  • Treatment (in clinic treatment, in home treatment)Treatment being tested

    Patients receive standard of care treatment in the clinic for 6-12 weeks then receive treatment in the home with CCBW for 12-24 weeks in the absence of disease progression or unacceptable toxicity. Patients receive any remaining treatment in the clinic.

    Treatment: Cancer Therapeutic Procedure, Health Care Delivery, and Questionnaire Administration

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 2 Pragmatic Clinical Trial to Evaluate Administration of Cancer Therapy in the Patients' Homes Versus in Clinic in Black Men With Advanced or Metastatic Prostate Cancer
Plain-language title
Tests cancer treatment given at home versus in clinic for prostate cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
6 November 2026